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Abstract
The nuclear bile acid receptor FXR (farnesoid-X-receptor) has recently been implicated in the
pathophysiology of non-alcoholic fatty liver disease because selective FXR-agonists improve glucose
and lipid metabolism in rodent models of obesity. However, the regulation of FXR and other relevant
nuclear receptors as well as their lipogenic target genes in fatty liver is still not revealed in detail. Livers
were harvested from 14-week-old male ob/ob mice and wild-type controls. Serum bile acids were
quantified by radioimmunoassay. mRNA and protein expression of transporters and nuclear receptors
was analyzed by reverse transcriptase-polymerase chain reaction and Western blotting, whereas DNA
binding to the IR-1 element was examined by electrophoretic mobility shift assay. In this study we
show: (i) bile acid retention in ob/ob mice, (ii) a resulting FXR upregulation and binding to the IR-1
element in ob/ob animals and (iii) concomitant activation of the fatty acid synthase as a potential
lipogenic FXR target gene in vivo. The present study suggests a potential role of hepatic bile acid
retention and FXR activation in the induction of lipogenic target genes. Differences between intestinal
and hepatic FXR could explain apparent contradictory information regarding its effects on fatty liver
disease.
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Abstract
The nuclear bile acid receptor FXR has recently been implicated in the pathophysiology of 
non-alcoholic fatty liver disease since selective FXR-agonists improve glucose and lipid 
metabolism in rodent models of obesity. However, the regulation of FXR and other relevant 
nuclear receptors as well as their lipogenic target genes in fatty liver is still not uncovered 
in detail. Livers were harvested from 14 week-old male ob/ob mice and wild-type controls. 
Serum bile acids were quantified by RIA. mRNA and protein expression of transporters and 
nuclear receptors was analyzed by RT-PCR and Western blotting, while DNA binding to the 
IR-1 element was examined by EMSA. In this study we show (i) bile acid retention in ob/ob 
mice, (ii) a resulting FXR upregulation and binding to the IR-1 element in ob/ob animals 
and (iii) concomitant activation of the fatty acid synthase as a potential lipogenic FXR target 
gene in vivo.  The present study suggests a potential role of hepatic bile acid retention and 
FXR activation in the induction of lipogenic target genes. Differences between intestinal and 
hepatic FXR may explain apparent contradictory information regarding its effects on fatty liver 
disease.
Keywords: bile acid transporters; cholestasis; FXR; non-alcoholic fatty liver disease; nuclear 
receptors; ob/ob mouse.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized condition that affects 
10 to 24% of the general population and comprises liver disorders ranging from steatosis and 
non-alcoholic steatohepatitis (NASH) to advanced fibrosis and cirrhosis (Angulo, 2002; Adams 
et al., 2005; Stefan et al., 2008; Erickson, 2009). The increasing global burden of obesity and 
related diseases highlights the necessity to define targeted future strategies of intervention 
based on pathophysiology.
Bile acids (BA) are physiological ligands of the nuclear bile acid receptor FXR (farnesoid-X-
receptor) that can be referred to as an intracellular bile-acid sensor which is the key regulator 
in bile acid homeostasis (Makishima et al., 1999). Recent studies in genetic mouse models 
of obesity and diabetes (db/db and ob/ob mice) highlight a link between FXR activation 
and development of the metabolic syndrome since treatment with its synthetic ligand 
GW4064 significantly improves insulin sensitivity (Cariou et al., 2006; Zhang et al., 2006). 
Hepatocellular bile acid retention is mainly caused by reduced canalicular bile salt secretion as 
the rate limiting step in transport. Decreased expression of canalicular transporters including 
the bile-salt export pump (BSEP/Bsep; encoded by ABCB11) and the conjugate export pump 
(multidrug resistance-associated protein; MRP2/Mrp2, encoded by ABCC2) have been 
described in various form of cholestasis (reviewed in Geier et al., 2007) and also in rodent 
models of fatty liver disease and diabetes (Pizarro et al., 2004; Geier et al., 2005b). As an 
adaptive response accumulating bile acids mediate a indirect negative feedback regulation 
of hepatocellular bile acid uptake transporters such as the high-affinity Na+-dependent bile-
salt transporter NTCP/Ntcp (encoded by SLC10A1) by an FXR-dependent activation of the 
transcriptional repressor small heterodimer partner (Shp) (Geier et al., 2007). Furthermore, 
bile acid-activated FXR represents a negative transcriptional regulator of cholesterol 7-α-
hydroxylase (CYP7A1) expression, which represents the rate-limiting enzyme in the de novo 
synthesis of bile acids from cholesterol (reviewed in Chiang, 2009). 
Interestingly, general FXR-/- mice not only exhibit elevated serum bile acid concentrations but 
also develop fatty liver which is severely aggravated when fed a 1% cholesterol diet (Sinal et 
al., 2000; Lambert et al., 2003). Several reports confirm an inverse correlation between bile 
acid-dependent FXR-pathway activation and plasma triglyceride levels since bile acid-feeding 
in different models of hypertriglyceridemia decreased de novo lipogenesis through down-
regulation of sterol regulatory element binding protein-1c (SREBP-1c) resulting in reduced 
plasma triglycerides (Watanabe et al., 2004; Bilz et al., 2006). 
Despite the central role of FXR and other nuclear receptors in bile acid and lipid metabolism, 
their endogenous expression in fatty livers is still elusive. These nuclear receptors undergo 
marked changes in their expression and activity during cholestasis and inflammation (Trauner 
et al., 1998; Denson et al., 2000; Geier et al., 2003, 2005b,c; Ghose et al., 2004; Zollner 
et al., 2005) both of which are characteristic of non-alcoholic fatty liver disease as well. 
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We hypothesize that bile acid accumulation in fatty livers leads to the activation of nuclear 
receptors, particularly FXR, and respective target genes under these specific conditions.
Therefore, aim of this study was to characterize the expression of FXR and other class II 
nuclear receptors in fatty livers of ob/ob mice and to elucidate potential effects of accumulating 
bile acids on lipogenic FXR-target genes under these conditions.
Results
Ob/ob mice develop liver steatosis without inflammation
Leptin-deficient ob/ob mice spontaneously developed hepatic steatosis at 14 weeks of age. 
In these animals hematoxylin-eosin staining of paraffin-embedded tissue sections evidenced 
a severe hepatic steatosis without signs of histopathological inflammation compared to 
unaffected wild-type controls (Figure 1A). The liver/body weight ratio of 14 weeks old ob/ob 
mice (9.0±0.2%) was increased in comparison to wild-type controls (5.0±0.4%; n=6 each). 
mRNA expression levels of proinflammatory cytokines are increased in ob/ob-mice compared 
to control animals (2.26±0.26 fold for IL-1β and 4.05±0.32 fold for tumor necrosis factor 
α (TNFα), 3.19±0.74 fold for IL-8 respectively ; n=6; p<0.05 each). No change was observed 
for IL-12 (data not shown) (Figure 1B).
Decreased bile acid transporter expression renders fatty livers in ob/ob mice cholestatic
Whether ob/ob mice are cholestatic as recently reported for fa/fa Zucker rats has not been 
investigated so far (Geier et al., 2005a). Serum bile acid concentrations as measured by radio 
immuno assay are increased 7-fold in ob/ob mice in comparison to wild type controls (14.9±5.4 
vs. 1.9±1.0 µM; n=6; p=0.00080) (Figure 3). 
Subsequently, hepatic bile salt and organic anion transporter expression in ob/ob mice has 
been determined at both mRNA and protein expression level using real-time RT-PCR and 
Western blot analysis (Figures 2 and 3). RNA expression of basolateral uptake transporters 
was significantly decreased for Oatp1a1 and Oatp1a4 (organic anion transporter) compared to 
control mice to 2±1 % and 55±6 %, respectively. Similarly, protein expression was reduced to 
9±1 % (Oatp1a1) and 11±6 % (Oatp1a4) (p<0.05 each). Whereas Ntcp mRNA expression was 
largely unchanged Ntcp protein levels were siginificantly decreased in ob/ob-mice compared 
to wild-type controls (70±9 %; p<0.05). In contrast to other basolateral transporters, Oatp2b1 
mRNA was significantly increased to 188±30 % of controls. Expression of basolateral export 
systems was strongly upregulated at the mRNA (Mrp3 332±45 %; Mrp4 1086±170 %) and 
protein level (Mrp4 618±65 %; p<0.05) each compared to controls. 
On the contrary to other rodent models of cholestasis but similar to fa/fa rats expression of 
canalicular transporters was mainly decreased at the protein level. Whereas Bsep and Mrp2 
mRNA expression levels were even increased in ob/ob mice to 234±40% and 168±16% of 
wild-type controls (p<0.05) microsomal protein levels were decreased to 59±10 % for Bsep 
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and 67±16 % for Mrp2 (p<0.05). 
Consistent with decreased transporter protein abundance and bile acid retention in cholestatic 
ob/ob mice Cyp7a1 mRNA expression is profoundly suppressed compared to non-cholestatic 
lean animals to 10± 4% (p=0.0001) (Figure 4A). 
FXR and other nuclear receptors are upregulated in ob/ob mice
In contrast to rodent models of inflammatory liver disease nuclear receptor activity is not 
suppressed in obese fa/fa rats (Geier et al., 2005a,b) To examine the influence of bile acid-
retention and induction of proinflammatory cytokines on nuclear receptors in ob/ob mice, 
we analyzed both mRNA and protein expression of several nuclear receptors implicated 
in bile acid-signalling including FXR, pregnane X receptor (PXR) and vitamin D receptor 
(VDR) (Figure 4). Most prominently, FXR nuclear protein was increased to 330±70 % 
(mRNA expression 196±21 %) in ob/ob mice compared to controls (p<0.05 each). VDR and 
PXR expression were similarly increased at both nuclear protein (225±43 % and 258±34 %, 
respectively) and mRNA levels (309±27 % and 130±26 %, respectively). Likewise, liver X 
receptor (LXR) protein and mRNA levels increased by 146±20 % and 169±19 % compared to 
the wild type. 
Finally, Shp mRNA and protein expression was analyzed to determine whether FXR activation 
results in the induction of this target gene. In contrast to other rodent models of cholestasis, Shp 
mRNA and protein expression in ob/ob mice were not significantly increased and comparable 
to their control littermates (Figure 4A). 
FXR DNA-binding activity and lipogenic target genes including fatty acid synthase are 
increased in ob/ob mice
To investigate whether the observed increase in FXR nuclear protein results in increased DNA 
binding activity and activation of respective target genes, we analyzed binding to the FXR-
responsive element IR-1 which is present in mouse promoters of the Bsep (bile salt export 
pump) and Fas (fatty acid synthase) gene (Ananthanarayanan et al., 2001; Matsukuma et al., 
2006) Using electrophoretic mobility shift assays DNA binding activity to the IR-1 element 
is doubled in nuclear extracts from obese mice (196±3 % compared to lean controls; p<0.05) 
(Figure 5). Following the trend of an increased mRNA expression of Bsep (see Figure 2), FAS 
mRNA expression as another FXR target gene was upregulated to 4982 ± 1432 % (p<0.05) 
(Figure 6) consistent with activated IR-1 binding. 
As expected other lipogenic genes including peroxisome proliferator activated receptor γ 
(PPARγ) mRNA and its target transcript Srebp-1c were upregulated in ob/ob mice 58-fold and 
7-fold (p<0.05 each), respectively (Figure 6). 
FXR in the pathogenesis of NAFLD in ob/ob-mice
Discussion
Previous evidence from obese fa/fa Zucker rats as an established model of non-alcoholic fatty 
liver disease, obesity and diabetes highlights the possibility that bile acid retention may play 
a role in the pathogenesis of the underlying metabolic disease (Pizarro et al., 2004; Geier et 
al., 2005b). We now used the ob/ob mouse model of fatty liver disease to further investigate 
potential bile acid-mediated effects on nuclear receptor activity and lipogenic target genes in 
more detail. This model resembles human fatty liver disease without histological inflammatory 
infiltrates and is characterized only by a subclinical extent of intrahepatic cytokine activation. 
The major new findings of the present study are (i) the bile acid retention in ob/ob mice 
rendering these animals by definition cholestatic, (ii) the resulting FXR upregulation and 
binding to the IR-1 element in ob/ob animals and (iii) the concomitant activation of the fatty 
acid synthase as lipogenic potential FXR target gene in vivo. 
In the current study we describe bile acid retention and FXR activation as a potential trigger 
in the pathogenesis of fatty liver disease in ob/ob mice. This retention of bile acids is well 
in accordance to preliminary data from human patients with fatty liver disease which are 
also characterized by an increase in serum bile acid concentrations (Aranha et al., 2008; 
Kocabayoglu et al., 2009). Cholestasis in mice with fatty livers is accompanied by a down-
regulation of canalicular bile acid transporter Bsep and Mrp2 proteins as the rate limiting 
step in bile acid secretion. Furthermore, there seems to be a lack in the cholestatic feedback 
inhibition of Ntcp in ob/ob mice (Figures 2 and 3). Differences between maintained RNA 
expression and slighthly decreased protein levels may be explained by posttranslational 
modification or compartimental changes in protein location. A rather moderate decrease in 
Ntcp and Bsep protein expression is in accordance with previous observations in fa/fa rats 
(Pizarro et al., 2004; Geier et al., 2005b). Dysregulation of NTCP is even more prominent in 
humans where higher mRNA expression levels have been linked to disease progression in 
human NAFLD (Kocabayoglu et al., 2009). Of note, Cheng and co-workers observed in ob/ob 
mice a decreased Ntcp (mRNA and protein) and Bsep (mRNA) expression and an even induced 
Mrp2 protein (mRNA unchanged compared to lean controls) (Cheng et al., 2008) which do 
not parallel other findings in humans (Martin et al., 2009), rats (Pizarro et al., 2004; Geier et 
al., 2005b) and mice with fatty livers. Discrepancies may be explained by different breeding 
conditions which are particularly relevant due to established changes in the intestinal barrier of 
ob/ob mice leading to changes in portal lipopolysaccharide levels that can contribute to hepatic 
inflammatory damage (Brun et al., 2007). Nevertheless, Cheng et al. report similar alterations 
in the expression of other basolateral bile acid transporters in ob/ob mice including the down-
regulation of Oatp1a1 and the induction of the overflow systems Mrp3 and Mrp4 in accordance 
with the present study (Cheng et al., 2008). 
The underlying molecular mechanisms leading to transporter dysregulation may be different 
from (obstructive) cholestasis. Hepatic FXR expression is upregulated in ob/ob mice at both 
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the mRNA and protein levels and as expected in the presence of bile acid retention FXR 
binding to the corresponding IR-1 element is activated (Figures 4 and 5). This is in line 
with a transcriptional activation of the FXR target gene Bsep via IR-1 binding but decreased 
Bsep protein necessitates the postulation of further posttranslational processing under these 
conditions (Figures 2, 3 and 5). However, we could not detect an upregulation of Shp as 
another FXR-target as previously shown for obstructive cholestasis (Zollner et al., 2005) either 
on the mRNA or protein level. These results regarding an absent Shp mRNA induction have 
been previously reported in obese ob/ob and db/db mouse models (Zhang et al., 2006; Miao 
et al., 2009). Miao and co-workers could further demonstrate that Shp protein abundance is 
highly controlled by ubiquitin-proteasomal degradation in wild-type animals whereas ob/ob 
mice are largely protected against Shp ubiquitination.
Irrespective of ameliorating effects of FXR activation on hepatic inflammation, fibrosis during 
steatohepatitis and lipid abnormalities in the mouse model (Cipriani et al., 2009; Zhang et 
al., 2009) the activation of FXR could also play a role for the dysregulation of lipogenesis in 
the pathogenesis of fatty liver disease. Recently, a FXR-responsive element (IR-1) has been 
identified within the mouse Fas promoter which mediates a bile acid-dependent upregulation 
of the Fas gene besides the established insulin-induced activation (Wang and Sul, 1998; 
Matsukuma et al., 2006). In the present study extremely high levels of Fas transcripts have 
been observed in ob/ob mice in the presence of increased IR-1 (FXR) binding (Figures 5 and 
6). A moderately increased Fas expression in both wild-type and obese KK-Ay mice upon 
long term feeding of cholic acid with a concurrent decrease of Srebp-1 support this concept in 
general (Watanabe et al., 2004).
Consistent with Fas activation the lipogenic transcription factor Srepb-1c and its upstream 
activators LXR, PPARγ and PXR are increased at the mRNA level (Figures 4 and 6). In 
primary mouse hepatocytes it has been shown that the activation of FXR by bile acids or 
synthetic agonists represses the expression of Srebp-1c and its lipogenic target genes in a Shp-
dependent manner (Watanabe et al., 2004). 
Under the special conditions present in the livers of ob/ob mice, activation of hepatic FXR 
may therefore affect the fatty acid homeostasis of hepatocytes, by activating FAS expression 
additionally to established Srebp-1c effects.
It is important to note that the role of FXR in the complex pathophysiological scenario of 
fatty liver disease is not conclusively clarified so far. Whereas a variety of data suggest the 
potentially beneficial role of bile acids in treatment of NAFLD one cannot yet unambiguously 
evaluate their usefulness (Orlando et al., 2007). Several interventional and knockout studies 
demonstrated beneficial effects of FXR activation. The general absence of FXR in vivo has 
profound consequences on systemic lipid metabolism since general Fxr-/- mice have increased 
serum triglycerides, cholesterol and free fatty acids and develop fatty livers (Sinal et al., 
2000; Lambert et al., 2003; Ma et al., 2006). On one hand, a inverse correlation between 
the activation of FXR pathways and plasma triglyceride levels exists since bile acid-feeding 
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in different models of hypertriglyceridemia decreased de novo lipogenesis through down-
regulation of Srebp-1c resulting in reduced plasma triglycerides (Watanabe et al., 2004; Bilz 
et al., 2006). But in contradiction, treatment of hyperlipidemic hamsters did not significantly 
decrease Srebp-1c expression despite a reduction in triglyceride synthesis (Bilz et al., 2006) 
and hepatic Srebp-1c mRNA levels are not increased in Fxr-/- mice as to be expected (Zhang et 
al., 2004; Duran-Sandoval et al., 2005a,b; Lefebvre et al., 2009).
Studies in db/db and ob/ob mice have shown that treatment with the synthetic FXR-
specific ligand GW4064 significantly improves insulin sensitivity and reduces hepatic lipid 
accumulation (Cariou et al., 2006; Zhang et al., 2006). Treatment with the FXR agonist 
GW4064 significantly represses hepatic CYP7A1 in mice with liver-specific deletion of Fxr 
(DeltaL) but not in mice with intestinal deletion of Fxr (DeltaIE), which opens the possibility 
that activation of FXR in intestine but not in the liver could mediate hepatic effects of GW4064 
(Kim et al., 2007). Keeping in mind that GW4064 is characterized by a poor pharmacokinetic 
profile with poor intestinal absorption into the circulation these studies do not necessarily 
rule out that hepatic FXR and its activation in fatty livers may play a causal role in the 
pathophysiology of fatty liver disease. To finally answer this question comparable studies using 
intestinal and liver specific FXR deletion in obese mice may be necessary.
In summary, our study opens the possibility that bile acid retention may contribute to the 
development of fatty liver disease. Understanding the multifaceted function of FXR in lipid 
homeostasis may contribute to pathophysiological and therapeutic concepts for a targeted 
treatment of fatty liver disease in the future. 
Materials and methods
Animals
Eight-week old male ob/ob mice (B6.V-Lepob/J) and age- and gender matched control animals 
C57BL/6J were purchased from The Jackson Laboratory (Bar Harbor, ME USA). All mice 
were housed in pathogen-free animal facilities under a standard 12-h light, 12-h dark cycle 
with access to regular rodent chow and autoclaved tap water ad libitum for six weeks. The 
mice were sacrificed - most of the liver tissue was immediately frozen in liquid nitrogen and a 
small portion was immersion fixed in 4% formalin. Subsequently, paraffin-embedded sections 
were analyzed after hematoxylin-eosin staining for the degree of hepatic steatosis. The animals 
received humane care and the study protocols were approved by the local Government sʼ 
Animal Care Committee.
mRNA isolation and real-time RT-PCR
Total RNA was isolated from liver by standard phenol chloroform extraction procedure using 
UltraspecTM (Biotecx Lab, Houston, TX, USA) according to manufacturerʼs instructions. 
mRNA was reverse-transcribed to cDNA using the Transcriptor First Strand cDNA Synthesis Kit 
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(Roche, Mannheim, Germany). cDNA was used for real-time PCR with SYBR Green Reagent 
(Invitrogen, Karlsruhe, Germany) and specific primer pairs on a 7300 ABI PRISM Real-Time 
PCR System and with ABI PRISM 7300 SDS software (Applied Biosystems, Foster City, 
CA, USA). Cyp7a1 expression was analyzed using ABI TaqMan probes. Expression was 
normalised against 18S. All primer sequences are available from the authors upon request.
Western blotting
Nuclear and microsomal protein fractions were prepared as described previously (Gartung et 
al., 1997). Similar amounts of microsomal and nuclear protein (50 µg and 10 µg, respectively) 
were separated by SDS-PAGE, transferred to a PVDF membrane and probed with the 
following antibodies: Oatp1a1 (Eckhardt et al., 1999), Oatp1a4 (Reichel et al., 1999), Ntcp 
(Stieger et al., 1994), BSEP (Gerloff et al., 1998), Mrp2 (Madon et al., 2000), Mrp4 (Rius et 
al., 2003), FXR (Santa Cruz, clone Q-20, sc-1205), LXR (Abcam, ab-28478), PXR (SantaCruz, 
clone A-20, sc-7737), VDR (Santa Cruz, clone C-20, sc-1008), SHP (Santa Cruz, clone Q-14, 
sc-15283). Na/K ATPase (abcam, ab-7671) and β-actin (Sigma, A2066) antibodies were used 
as loading control for microsomal and total protein. After incubation with species-specific 
HRP-conjugated secondary antibody (Dako, Hamburg, Germany) immune complexes were 
detected using the ECL detection kit (GE Healthcare, Freiburg, Germany). Densitometric 
quantification of Western blots was performed using Quantity One software (Bio-Rad, Munich, 
Germany).
Electrophoretic mobility shift assay
Nuclear protein extracts were prepared as described previously (Geier et al., 2002). DNA 
binding analyses were carried out using the Lightshift Chemiluminescent EMSA kit (Pierce 
Biotechnology, Rockford, IL, USA) according to the manufacturers  ʼprotocol. The following 
oligonucleotides were used as probes in the analyses: IR-1, sense 5ʼ-CTT TAG GCC ATT GAC 
CTA TAA-3  ʼand antisense 5ʼ-TTA TAG GTC AAT GGC CTA AAG-3  ʼ(Geier et al., 2005b). 
These oligonucleotides were end-labeled using the biotin 3  ʼend DNA labelling kit (Pierce 
Biotechnology). Binding reactions consisted of 1 × binding buffer, 50 ng/µl poly dIdC, 20 fmol 
biotin-labeled DNA and 5 µg nuclear protein in a 20 µl reaction. Competition experiments 
included 6 pmol unlabelled oligonucleotide (300-fold molar excess). Densitometric 
quantification was performed using Quantity One software (Bio-Rad).
Bile acid quantification
Serum bile acids were measured by radioimmuno assay using a Bile Acid RIA Kit (MP 
Biomedicals, Ilkirch, France) according to the manufacturerʼs specifications.
Statistical analysis
Statistical significance (p<0.05) between control animals and ob/ob-mice was determined by 
FXR in the pathogenesis of NAFLD in ob/ob-mice
Studentʼs t-test. Data represent the mean ± standard deviation.
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Figure legends
Figure 1  Liver histology and expression of inflammatory cytokines in ob/ob mice. 
(A) Representative hematoxylin and eosin staining of liver sections from wild-type and ob/
ob mice (200x-magnification). Accumulation of hepatocellular lipid vacuoles are present in 
ob/ob livers (right) compared to wild type livers with normal histological appearance (left). 
(B) Analysis of inflammatory cytokine gene expression. Quantitative RT-PCR was performed 
with RNA samples isolated from liver of controls and ob/ob-mice (n=6). The asterisk indicates 
p<0.05 as determined by the Studentʼs t-test.
Figure 2  Hepatic transporter gene expression is altered in ob/ob mice. 
Quantitative TaqMan RT-PCR was performed with RNA samples isolated from liver of controls 
and ob/ob-mice (n=6). The asterisk indicates p<0.05 as determined by the Studentʼs t-test.
Figure 3  Western blot analysis of hepatic transporter protein expression in ob/ob mice and 
Serum bile acid concentration in ob/ob mice. 
(A) Western blotting: microsomal protein of wild type and ob/ob mice (n=6 each) was separated 
by SDS-PAGE (protein loading 50 µg/lane), blotted onto a PVDF membrane and detected by 
specific antibodies. (B) Densitometric analysis: quantification of relative protein expression 
compared to wild-type animals. The asterisk indicates p<0.05 as determined by the Studentʼs 
t-test. (C) Serum from wild type and ob/ob animals was collected. Serum bile acids were 
measured by radioimmuno assay. Asterisk indicates p<0.05 as determined by the Studentʼs t-
test.
Figure 4  Nuclear receptor mRNA and protein expression in ob/ob mice. 
(A) mRNA expression: quantitative TaqMan RT-PCR was performed with RNA samples 
isolated from liver of controls and ob/ob-mice (n=6). (B) Western blot analysis: nuclear protein 
and whole cell extract (SHP) were separated by SDS-PAGE (protein loading 10 µg/lane), 
blotted onto a PVDF membrane and detected by specific antibodies. (C) Densitometric analysis: 
quantification of relative protein expression shown in B compared to wild-type mice. The 
asterisk indicates p<0.05 as determined by the Studentʼs t-test.
Figure 5  DNA-binding activity of FXR to the corresponding IR-1 element. 
DNA-binding analysis was performed with nuclear proteins obtained from liver tissue 
of control and ob/ob mice (n=4 each). Nuclear protein was incubated with biotin-labeled 
oligonucleotides representing the IR-1 element. Specificity of binding was confirmed by 
inclusion of specific competitor (SC) oligonucleotide or an unrelated oligonucleotide at a 300-
fold molar excess (NSC = non specific competitor). 
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Figure 6  Hepatic mRNA expression of lipogenic genes in ob/ob mice. 
Quantitative TaqMan RT-PCR was performed with RNA samples isolated from liver of 
controls and ob/ob-mice (n=6). Asterisk indicates p<0.05 as determined by the Studentʼs t-test.
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